Opthea Developing Therapy for Eye Diseases
Opthea is a public Australian biotechnology company (ASX:OPT) developing a novel biologic therapy, OPT-302, for the treatment of eye diseases.
OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 in wet AMD patients.
Opthea is currently enrolling patients in a Phase 2b clinical trial for patients with wet AMD and a Phase 1b/2a clinical trial in patients with DME.